Elbert Glover

Last updated

Elbert D. Glover
Glover Photo.jpg
Born1945 (age 79–80)
Kingsville, Texas, U.S.
NationalityAmerican
Alma materTexas Tech University, Texas A&M–Kingsville, Texas Woman's University
Occupation(s)Public health researcher, editor
Known forTobacco cessation research, founding editor of American Journal of Health Behavior

Elbert D. Glover (born May 14, 1946) is an American researcher and author in the field of tobacco addiction and smoking cessation. He retired as professor emeritus at the University of Maryland at College Park School of Public Health where he served as Chairperson of the Department of Behavioral and Community Health from 2005 to his retirement in 2015. [1] [2] He has worked as an entrepreneur, editor, and publisher, and was involved in the founding and management of the journals Health Behavior and Policy Review, [1] [2] American Journal of Health Behavior , [1] [2] [3] and Tobacco Regulatory Science. [1] [2] [3] [4] Glover was also one of the founders [1] [2] [5] of the American Academy of Health Behavior and served as its first president from 1997 to 2001. [1] [2] [6]

Contents

Early life and education

Glover was born at the Kingsville Naval Base in Kingsville, Texas, in 1945, where his father was stationed in the U.S. Navy. [7] He graduated from Roy Miller High School in Corpus Christi, Texas in 1963 and attended Texas Tech University on a football scholarship, graduating in 1969. [1] [2] [8] He earned a master's degree from Texas A&M Kingsville in 1972, [1] [2] and a PhD in health education from Texas Woman's University in 1977. [1] [2] [5] [8]

Career

Glover held teaching and administrative positions at several institutions, including visiting assistant professor at Texas A&M University (1975–1976), assistant professor at the University of Kansas (1976–1978) and Texas Christian University (1978–1982), and associate professor and chair at Oklahoma State University (1982–1983). [1] [2] He became associate professor at East Carolina University (1985–1988), where he was later promoted to professor. He also served as professor at Pennsylvania State University (1988–1990), and held a faculty role in behavioral medicine and psychiatry at West Virginia University School of Medicine (1990–2005), where he directed the Tobacco Research Center. At the University of Maryland School of Public Health, he served as professor and department chair (2005–2015), founded the Center for Health Behavior Research, and retired in 2015 as professor emeritus. [1] [2] [8]

Research

Glover's research initially focused on smokeless tobacco; [1] [2] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] however, his primary research interest progressed to the development and testing of pharmacological cessation aids for smokers interested in stopping the addiction of tobacco. He conducted clinical trials with the use of all delivery forms of nicotine available on the US and European markets, to include nicotine gum, [18] [19] transdermal patches, [20] [21] oral nicotine inhalers, [22] nasal spray, [23] and sublingual tablets. [24] [25] Glover also conducted trials with bupropion (Zyban, a monocyclic antidepressant) [26] [27] [28] [29] [30] [31] [32] and varenicline (Chantix, a nicotine receptor and partial agonist) which resulted in both being approved for use in the US. [33] [34] [35] [36] In addition, he studied the use of lobeline as a nicotine blocker, [37] [38] and various psychoactive substances including anti-depressants and anti-anxiety agents. [39] He also investigated rimonabant (a cannabinoid receptor inverse agonist), and 3′AmNic-rEPA (a nicotine conjugate vaccine) as smoking cessation aids. [1] [2]

He received research grants from the government U.S. Department of Education, Centers for Disease Control, National Cancer Institute, National Institute of Drug Abuse, and National Institutes of Health. Also, received grants from the manufacturers of smoking cessation aids and conducted various pharmaceutical testing for many companies. [1] [2] [13] [18] [20]

Professional accomplishments

Glover has authored or co-authored 146 peer-reviewed articles and an additional 63 professional publications from 1976 to 2021 and received approximately $33 million in grant funding. [1] He has delivered over 550 invited medical grand rounds/workshops on the subject to physicians and presented 335 national and international professional presentations to various medical and health professional organizations. [1] [2] [3] [4]

Glover was owner, publisher and editor of the American Journal of Health Behavior , Health Behavior and Policy Review and Tobacco Regulatory Science . [1] [2] [3] [4] In 2020, he sold his major portion of Health Behavior and Policy Review and in 2021 sold the American Journal of Health Behavior and Tobacco Regulatory Science. He was the founder (1997) and first president (1997–2001), of the American Academy of Health Behavior where he was named Fellow (1998), Research Laureate (2008) and awarded the Lifetime Achievement Award (2000) by the academy. [1] He was selected as fellow of the American School Health Association & the Royal Institute of Public Health. He was elected Fellow (1991) and received the Distinguished Scholar Award from the American Association of Health Education (2003). [40] Moreover, he received the AAHPERD Alliance Scholar Award being only the 4th health educator in its history to receive this award (2005). [41]

Public work

Glover's work appeared or featured on many television programs, including Dateline, 20/20, The Charlie Rose Show, Good Morning America , PM Magazine, Health Talk America, MD-TV, CBS Morning News, Peter Jennings News World Report, and NBC Evening News. His research has also been featured in numerous popular publications such as Ladies Home Journal, Newsweek, Reader's Digest, Seventeen, Time , and USA Today . [1] [2]

He served in various capacities primarily as reviewer and ad hoc reviewer for 20 key health academic journals and/or publications among these are the American Journal of Public Health, Addictive Behaviors, NCI Journal, Journal Clinical Advances in Smoking Cessation, Physician and Sports medicine, Medical Self-Care, Public Health Reports, American Journal of Health Education, Journal of School Health, Journal of Family Practice, Journal of Alcohol and Drug Education, Advances in Dental Research, Mayo Clinic Proceedings, Southern Medical Journal, Nicotine & Tobacco Research, Drug Discovery Today, and the Journal of the American Medical Association . [1] [2]

Criticism and controversy

In May–June 2021, the American Journal of Health Behavior published a controversial "Special Issue on JUUL", funded entirely by JUUL Labs. Critics noted that reviewers were not informed of the funding source during peer review, raising concerns of transparency and bias. Glover, the editor, later acknowledged the omission and stated he did not consider it a conflict. The practice of offering reviewers financial compensation and charging article authors significant publication fees also drew criticism. [42] [43] [44] Three members of the editorial board resigned in protest. Glover defended the journal's vetting procedures but retired soon afterward, citing a cancer diagnosis. [45]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 "Elbert D. Glover". University of Maryland | School of Public Health. Retrieved May 26, 2022.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Rowe, Steven. "Philosophy, Objectives and Scope of the Journal". Health Behavior and Policy Review. Retrieved May 26, 2022.
  3. 1 2 3 4 "Philosophy of the Journal". American Journal of Health Behavior. Retrieved May 26, 2022.
  4. 1 2 3 "Tobacco Regulatory Science (TRS)". Tobacco Regulatory Science. Retrieved May 26, 2022.
  5. 1 2 "AAHB Founders". American Academy of Health Behavior. Retrieved May 26, 2022.
  6. ↑ "Past Presidents". American Academy of Health Behavior. Retrieved May 26, 2022.
  7. ↑ Sapere Aude — Dare to Be Wise: Elbert D. Glover. New Prairie Press
  8. 1 2 3 4 "Elbert D. Glover". University of Maryland | School of Public Health. Retrieved May 27, 2022.
  9. ↑ Brown V. (December 4, 1985). "Lawsuit Says Snuff Killed Teen-Ager". The Washington Post. ISSN 0190-8286. Retrieved August 1, 2017.
  10. ↑ Blumenfeld L. (April 2, 1992). "Focus". The Washington Post. ISSN 0190-8286. Retrieved August 1, 2017.
  11. ↑ Boul D. (August 23, 1987). "What's New in Tobacco; His and Hers Chewing and Dipping". The New York Times . ISSN 0362-4331. Retrieved August 1, 2017.
  12. ↑ Glover, Elbert D.; Christen, Arden G.; Henderson, Allen H. (February 1982). "Smokeless Tobacco and the Adolescent Male" . The Journal of Early Adolescence. 2 (1): 1–13. doi:10.1177/027243168200200102. ISSN   0272-4316.
  13. 1 2 Schaefer, S. D.; Henderson, A. H.; Glover, E. D.; Christen, A. G. (October 1, 1985). "Patterns of Use and Incidence of Smokeless Tobacco Consumption in School-age Children" . Archives of Otolaryngology–Head and Neck Surgery. 111 (10): 639–642. doi:10.1001/archotol.1985.00800120033002. ISSN   0886-4470. PMID   4041171.
  14. ↑ Edmundson, Elizabeth W.; Glover, Elbert D.; Alston, Paul P.; Holbert, Donald (January 1987). "Personality Traits of Smokeless Tobacco Users and Nonusers: A Comparison" . International Journal of the Addictions. 22 (7): 671–683. doi:10.3109/10826088709027450. ISSN   0020-773X. PMID   3623750.
  15. ↑ Glover, E. D.; Edmundson, E. W.; Alston, P. P.; Holbert, D.; Schroeder, K. L. (1987). "Prevalence and patterns of smokeless tobacco use in a southeastern university". Journal of Drug Education. 17 (3): 201–211. doi:10.2190/M5CE-PKEQ-T720-VAU1. ISSN   0047-2379. PMID   3681594.
  16. ↑ Glover, Elbert D.; Schroeder, Kathleen L.; Henningfield, Jack E.; Severson, Herbert H.; Christen, Arden G. (December 1988). "An Interpretative Review of Smokeless Tobacco Research in the United States: Part I" . Journal of Drug Education. 18 (4): 285–310. doi:10.2190/4WLV-N0K3-C08Y-3528. ISSN   0047-2379. PMID   3065469.
  17. ↑ Glover, Elbert D.; Schroeder, Kathleen L.; Henningfield, Jack E.; Severson, Herbert H.; Christen, Arden G. (March 1989). "An Interpretative Review of Smokeless Tobacco Research in the United States: Part II" . Journal of Drug Education. 19 (1): 1–19. doi:10.2190/BTFE-R9E0-BM6N-LBEA. ISSN   0047-2379. PMID   2656965.
  18. 1 2 Glover, Elbert D.; Sachs, David P.L.; Stitzer, Maxine L.; Rennard, Stephen I.; Wadland, William C.; Pomerleau, Ovide F.; Nowak, Robert T.; Daughton, David M.; Glover, Penny N.; Hughes, John R.; Gross, Janet (1996). "Smoking Cessation in Highly Dependent Smokers with 4 mg Nicotine Polacrilex". American Journal of Health Behavior. 20 (5): 319–332. ISSN   1087-3244.
  19. ↑ Niaura, Raymond; Sayette, Michael; Shiffman, Saul; Glover, Elbert D.; Nides, Mitch; Shelanski, Morris; Shadel, William; Koslo, Randy; Robbins, Bruce; Sorrentino, Jim (November 2005). "Comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving". Addiction. 100 (11): 1720–1730. doi:10.1111/j.1360-0443.2005.01218.x. ISSN   0965-2140. PMID   16277632.
  20. 1 2 Glover, E. D. (January 30, 1992). "Transdermal nicotine patch for smoking cessation". The New England Journal of Medicine. 326 (5): 344–345. doi:10.1056/NEJM199201303260512. ISSN   0028-4793. PMID   1728741.
  21. ↑ Daughton, D. M.; Fortmann, S. P.; Glover, E. D.; Hatsukami, D. K.; Heatley, S. A.; Lichtenstein, E.; Repsher, L.; Millatmal, T.; Killen, J. D.; Nowak, R. T.; Ullrich, F.; Patil, K. D.; Rennard, S. I. (February 1999). "The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day". Preventive Medicine. 28 (2): 113–118. doi:10.1006/pmed.1998.0391. ISSN   0091-7435. PMID   10048102.
  22. ↑ Rennard, Stephen I.; Glover, Elbert D.; Leischow, Scott; Daughton, David M.; Glover, Penny N.; Muramoto, Myra; Franzon, Mikael; Danielsson, Tobias; Landfeldt, Björn; Westin, Ake (August 2006). "Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial". Nicotine & Tobacco Research. 8 (4): 555–564. doi:10.1080/14622200600789916. ISSN   1462-2203. PMID   16920653.
  23. ↑ Glover ED, Glover PN, Abrons HL, Franzon M (1997). "Smoking Cessation Among COPD and Chronic Bronchitis Patients Using the Nicotine Nasal Spray". American Journal of Health Behavior. 21 (4): 310–317.
  24. ↑ Glover ED, Glover PN, Franzon M, Sullivan CR, Howell GM, Keyes G (1997). "A Nicotine Sublingual Tablet for Smoking Cessation: 6-Month Data". 10th World Conference on Tobacco or Health, Abstract Book, 1997; Aug 24-27, Beijing, China. p. 138.
  25. ↑ Glover, Elbert D.; Glover, Penny N.; Franzon, Mikael; Sullivan, C. Rollynn; Cerullo, Connie C.; Howell, Robert M.; Keyes, Gordon G.; Nilsson, Fredrik; Hobbs, Gerald R. (November 2002). "A comparison of a nicotine sublingual tablet and placebo for smoking cessation". Nicotine & Tobacco Research. 4 (4): 441–450. doi:10.1080/1462220021000018443. ISSN   1462-2203. PMID   12521403.
  26. ↑ Hurt, R. D.; Sachs, D. P.; Glover, E. D.; Offord, K. P.; Johnston, J. A.; Dale, L. C.; Khayrallah, M. A.; Schroeder, D. R.; Glover, P. N.; Sullivan, C. R.; Croghan, I. T.; Sullivan, P. M. (October 23, 1997). "A comparison of sustained-release bupropion and placebo for smoking cessation". The New England Journal of Medicine. 337 (17): 1195–1202. doi:10.1056/NEJM199710233371703. ISSN   0028-4793. PMID   9337378.
  27. ↑ Hayford, K. E.; Patten, C. A.; Rummans, T. A.; Schroeder, D. R.; Offord, K. P.; Croghan, I. T.; Glover, E. D.; Sachs, D. P.; Hurt, R. D. (February 1999). "Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism". The British Journal of Psychiatry: The Journal of Mental Science. 174: 173–178. doi:10.1192/bjp.174.2.173. ISSN   0007-1250. PMID   10211174.
  28. ↑ Glover ED, Tucker VL, Winter PD (July 2000). "P.14.32 Efficacy and tolerability of bupropion sustained-release for smoking cessation: a review of pivotal studies". The International Journal of Neuropsychopharmacology. 3 (S1): S326. doi:10.1017/S1461145700009998.
  29. ↑ Dale, L. C.; Glover, E. D.; Sachs, D. P.; Schroeder, D. R.; Offord, K. P.; Croghan, I. T.; Hurt, R. D. (May 2001). "Bupropion for smoking cessation: predictors of successful outcome". Chest. 119 (5): 1357–1364. doi:10.1378/chest.119.5.1357. ISSN   0012-3692. PMID   11348939.
  30. ↑ Johnston, J. A.; Fiedler-Kelly, J.; Glover, E. D.; Sachs, D. P.; Grasela, T. H.; DeVeaugh-Geiss, J. (May 2001). "Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation". Nicotine & Tobacco Research. 3 (2): 131–140. doi:10.1080/14622200110042852. ISSN   1462-2203. PMID   11403727.
  31. ↑ Glover, Elbert D.; Glover, Penny N.; Sullivan, C. Rollynn; Cerullo, Connie L.; Hobbs, Gerald (2002). "A comparison of sustained-release bupropion and placebo for smokeless tobacco cessation". American Journal of Health Behavior. 26 (5): 386–393. doi:10.5993/ajhb.26.5.7. ISSN   1087-3244. PMID   12206448.
  32. ↑ Dale, Lowell C.; Ebbert, Jon O.; Glover, Elbert D.; Croghan, Ivana T.; Schroeder, Darrell R.; Severson, Herbert H.; Hurt, Richard D. (September 6, 2007). "Bupropion SR for the treatment of smokeless tobacco use". Drug and Alcohol Dependence. 90 (1): 56–63. doi:10.1016/j.drugalcdep.2007.02.008. ISSN   0376-8716. PMC   1994655 . PMID   17353101.
  33. ↑ Glover, Elbert D.; Rath, Jessica M. (August 2007). "Varenicline: progress in smoking cessation treatment". Expert Opinion on Pharmacotherapy. 8 (11): 1757–1767. doi:10.1517/14656566.8.11.1757. ISSN   1744-7666. PMID   17685891.
  34. ↑ Nides, Mitchell; Glover, Elbert D.; Reus, Victor I.; Christen, Arden G.; Make, Barry J.; Billing, Clare B.; Williams, Kathryn E. (2008). "Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis". American Journal of Health Behavior. 32 (6): 664–675. doi:10.5993/AJHB.32.6.10. ISSN   1087-3244. PMID   18442345.
  35. ↑ Cooke CE, Glover ED, Xing S, Lee HY. "Failure to obtain Varenicline in members with pharmacy benefits". The American Journal of Pharmacy Benefits, 2011;May/June 3(3):e36–e40
  36. ↑ Glover, Elbert D; Rath, Jessica M (August 2007). "Varenicline: progress in smoking cessation treatment" . Expert Opinion on Pharmacotherapy. 8 (11): 1757–1767. doi:10.1517/14656566.8.11.1757. ISSN   1465-6566. PMID   17685891.
  37. ↑ Glover ED, Leischow SJ, Rennard SI, Glover PN, Daughton D, Quiring JN, Schneider FH, Mione PJ. "Lobeline sulfate for smoking cessation: a pilot study". American Journal of Health Behavior, 1998;22(1):62–74.
  38. ↑ Glover, Elbert (2010). "A Multicenter Phase 3 Trial of Lobeline Sulfate for Smoking Cessation" . American Journal of Health Behavior. 34 (1): 101–109. doi:10.5993/AJHB.34.1.12. PMID   19663757.
  39. ↑ Glover, Elbert D.; Laflin, Molly T.; Schuh, Kory J.; Schuh, Leslie M.; Nides, Mitch; Christen, Arden G.; Glover, Penny N.; Strnad, Julia V. (May 2007). "A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers". Addiction. 102 (5): 795–802. doi:10.1111/j.1360-0443.2007.01763.x. ISSN   0965-2140. PMID   17506156.
  40. ↑ Glover, Elbert D. (2004). "A New Health Education Paradigm: Uncommon Thoughts about Common Matters". American Journal of Health Education. 35 (5): 260–271. ISSN   1055-6699.
  41. ↑ Glover, Elbert D. (January 2006). "Successfully Treating Nicotine Dependence" . American Journal of Health Education. 37 (1): 6–14. doi:10.1080/19325037.2006.10598872. ISSN   1932-5037.
  42. ↑ Kaplan, Sheila (July 5, 2021). "Juul Is Fighting to Keep Its E-Cigarettes on the U.S. Market". The New York Times. ISSN   0362-4331 . Retrieved July 10, 2021.
  43. ↑ "Individual Subscription & Renewal". American Journal of Health Behavior. Retrieved July 10, 2021.
  44. ↑ McCullough, Marie (July 10, 2021). "In a fight for survival, Juul funds pro-vaping studies, then pays a scholarly journal to showcase them". The Philadelphia Inquirer . Retrieved July 10, 2021.
  45. ↑ Dayen, David (July 7, 2021). "Juul: Taking Academic Corruption to a New Level". The American Prospect . Retrieved August 2, 2021.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.